(Q50191687)

English

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

scientific article published on 17 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

expanded access

1 reference

based on heuristic

inferred from title

metastatic melanoma

1 reference

based on heuristic

inferred from title

Diana Giannarelli

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Riccardo Danielli

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Anna Maria Di Giacomo

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ester Fonsatti

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Erica Bertocci

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Isabella Pesce

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Carolina Fazio

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ornella Cutaia

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Clelia Miracco

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Maurizio Biagioli

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Maresa Altomonte

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

17 April 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

62

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1021-1028

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

https://scigraph.springernature.com/pub.10.1007/s00262-013-1418-6

0 references

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Cutaneous melanoma: available therapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Advances in systemic treatment of melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Biomarkers on melanoma patient T cells associated with ipilimumab treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Management of immune-related adverse events and kinetics of response with ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Effector functions of donor-reactive CD8 memory T cells are dependent on ICOS induced during division in cardiac grafts

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

T-cell co-stimulation through B7RP-1 and ICOS

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1418-6

21 January 2018

Identifiers

10.1007/S00262-013-1418-6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23591982%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50191687&oldid=1404692285"